Why the study?
Does Ramipril reduce the risk of future cardiovascular events in high-risk patients without low ventricular ejection fraction or heart failure?
Population
High-risk population of men and women, including many with diabetes, not known to have low ventricular…
Design
Review, randomized
Authors
Loading...
Supports ramipril for high-risk prevention; leaves open applicability in contemporary cohorts with modern therapies.
Does Ramipril reduce the risk of future cardiovascular events in high-risk patients without low ventricular ejection fraction or heart failure?
The HOPE study demonstrated that Ramipril safely and cost-effectively reduces cardiovascular events in high-risk patients without heart failure, establishing its role in cardiovascular prevention.
McQueen et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: